almonertinib

Almonertinib is an orally administered, third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed in China. It selectively targets both EGFR-sensitizing mutations and the T790M resistance mutation, which are common drivers of non-small cell lung cancer (NSCLC). Almonertinib inhibits tumor cell proliferation, invasion, and migration while promoting apoptosis in EGFR-mutant NSCLC cells. It has demonstrated efficacy in patients with advanced or metastatic EGFR-mutated NSCLC who have progressed after prior EGFR TKI therapy. The drug is approved for use in China and has shown promising results as first-line therapy for patients with CNS metastases from EGFR-mutated NSCLC[1][3][4][6][8].

Brand names

阿美替尼

Other names

aumolertinibHS 10296HS10296HS-10296almonertinib hydrochloride盐酸阿美替尼